

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Application Number	10/562,085
-------	---	----	---	--------------------	------------

Complete if Known

Filing Date	December 23, 2005
First Named Inventor	Bernard Verrier
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	033339/305755

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-4,897,426	01-30-1990	Llinas et al.	
	2	US-6,359,015 B1	03-19-2002	Charness et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	3	WO 02/062327 A2	08-15-2002	Likhodi et al.		

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	English Language Translation Attached
	4	Gribkoff et al., "The Substituted Benzimidazolone NS004 Is an Opener of the Cystic Fibrosis Chloride Channel," <i>The Journal of Biological Chemistry</i> , Vol. 269, No. 15, Issue of April 15, 1994, pp. 10983-10986.	
	5	Copy of the International Search Report for PCT/FR2004/001662, completed December 1, 2004.	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.